Cargando…
Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
The influx of multiple novel therapeutic options in the mRCC field has brought a challenge for treatment sequencing in this disease. In the past few years, cabozantinib, nivolumab and the combination of lenvatinib and everolimus have been approved in the second-line setting. As there is no direct co...
Autores principales: | Maia, Manuel Caitano, Dizman, Nazli, Salgia, Meghan, Pal, Sumanta Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179120/ https://www.ncbi.nlm.nih.gov/pubmed/30334001 http://dx.doi.org/10.3233/KCA-170006 |
Ejemplares similares
-
Metastasis in renal cell carcinoma: Biology and implications for therapy
por: Gong, Jun, et al.
Publicado: (2016) -
Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2018) -
Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
por: Maia, Manuel Caitano, et al.
Publicado: (2017) -
Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021) -
Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma
in Brazil
por: Bergerot, Paulo G., et al.
Publicado: (2017)